List of Incivek drug patents

Incivek is owned by Vertex Pharms.

Incivek contains Telaprevir.

Incivek has a total of 2 drug patents out of which 0 drug patents have expired.

Incivek was authorised for market use on 23 May, 2011.

Incivek is available in tablet;oral dosage forms.

Incivek can be used as method of treating chronic hepatitis c.

The generics of Incivek are possible to be released after 30 May, 2028.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7820671 VERTEX PHARMS Peptidomimetic protease inhibitors
Feb, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8431615 VERTEX PHARMS Dose forms
May, 2028

(5 years from now)

Drugs and Companies using TELAPREVIR ingredient

Market Authorisation Date: 23 May, 2011

Treatment: Method of treating chronic hepatitis c

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in